Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Therapeutic value of new drugs assessed with Ahlqvist-Rastad’s rating system

From: Assessment of the therapeutic value of new medicines marketed in Australia

Ahlqvist-Rastad’s rating system

  

N

%

Drug for conditions with no currently available treatment

A

 

0

0.0

Added therapeutic value*

B

B1

18

30.5

 

B4

1

1.7

 

Subtotal

19

32.2

Similar therapeutic value**

C

C1

5

8.5

 

C2

20

33.9

 

Subtotal

25

42.4

Inferior therapeutic value***

D

D1

2

3.4

 

D2

3

5.1

 

Subtotal

5

8.5

Uncertain therapeutic value****

E

 

10

16.9

TOTAL

  

59

100.0

  1. *The effect (B1)/ safety (B2)/ dosage (B3)/ route of administration (B4) seems to be better for patients than that of previously licensed alternatives.
  2. ** First medicine of a new class of agents with similar therapeutic value to that of previously licensed alternatives (C1).
  3. New agent of an existing class with similar therapeutic value to that of previously licensed alternatives (C2).
  4. *** First medicine of a new class with inferior therapeutic value to that of previously licensed alternatives (D1).
  5. New agent of an existing class with inferior therapeutic value to that of previously licensed alternatives (D2).
  6. ****New agent whose therapeutic value remains unknown because evaluation is limited to its effects on surrogate end points.